Binary Long on ACHV: Betting on Cytisinicline Approval and a 2026 Commercial Kickoff
Achieve Life Sciences (ACHV) is a late-stage biotech focused on cytisinicline for smoking and vaping cessation. With an FDA review expected in June 2026, a successful approval could re-rate the company well above its current $225M market cap. This trade idea outlines an actionable long with entry, stop, targets, catalysts, and a clear risk framewor…